Setmelanotide: all 25 studies that test it

Page 1 of 1. Open to participants first (3), then studies with results posted, then the rest; newest registration first within each.

• Real-World Effects of MC4R Agonist Therapy in BBS and Severe Genetic ObesityRecruitingNCT07674290Phase 4
• Setmelanotide to Treat Obesity in a Patient With Pseudohypoparathyroidism Type 1a (PHP1a)Enrolling by invitationNCT07496463Phase 2
• A Trial of Setmelanotide in Patients With Congenital Hypothalamic Obesity (Sub-study of NCT05774756)RecruitingNCT06760546Phase 3
• A Trial of Setmelanotide in Acquired Hypothalamic ObesityActive, not recruitingNCT05774756Phase 3Results posted
• Phase 3 Crossover Trial of Two Formulations of Setmelanotide in Participants With Specific Gene Defects in the MC4R PathwayCompletedNCT05194124Phase 3Results posted
• Study of Setmelanotide Effects on QTc (Corrected QT) Interval in Healthy ParticipantsCompletedNCT05046132Phase 4Results posted
• Setmelanotide in Pediatric Participants With Rare Genetic Diseases of ObesityCompletedNCT04966741Phase 3Results posted
• DAYBREAK: A Study of Setmelanotide in Participants With Specific Gene Variants in the Melanocortin-4 Receptor (MC4R) PathwayCompletedNCT04963231Phase 2Results posted
• Open-Label Study of Setmelanotide in Hypothalamic ObesityCompletedNCT04725240Phase 2Results posted
• Setmelanotide (RM-493), Melanocortin-4 Receptor (MC4R) Agonist, in Bardet-Biedl Syndrome (BBS) and Alström Syndrome (AS) Participants With Moderate to Severe ObesityCompletedNCT03746522Phase 3Results posted
• Long Term Extension Trial of SetmelanotideCompletedNCT03651765Phase 2/3Results posted
• Setmelanotide for the Treatment of Leptin Receptor (LEPR) Deficiency ObesityCompletedNCT03287960Phase 3Results posted
• Setmelanotide Phase 2 Treatment Trial in Participants With Rare Genetic Disorders of ObesityCompletedNCT03013543Phase 2Results posted
• Setmelanotide for the Treatment of Early-Onset Pro-Opiomelanocortin (POMC) Deficiency ObesityCompletedNCT02896192Phase 3Results posted
• Phase 2 Trial to Evaluate Safety and Efficacy of Setmelanotide (RM-493) in Obese Participants With Prader-Willi SyndromeCompletedNCT02311673Phase 2Results posted
• Phase 1b/2a Study to Evaluate Safety and Efficacy of Setmelanotide in Obese PatientsCompletedNCT02041195Phase 1/2Results posted
• Phase 2 Study to Evaluate Safety and Efficacy of RM-493 in Obese ParticipantsCompletedNCT01749137Phase 2Results posted
• A Study of Setmelanotide in Patients With Prader-Willi SyndromeActive, not recruitingNCT06772597Phase 2
• Open-Label Extension Study of SetmelanotideCompletedNCT06596135Phase 3
• EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R PathwayCompletedNCT05093634Phase 3
• A Phase 1 Study to Evaluate the Pharmacokinetics of Setmelanotide in Subjects With Varying Degrees of Renal ImpairmentCompletedNCT04348175Phase 1
• Setmelanotide in a Single Patient With Partial LipodystrophyCompletedNCT03262610Phase 2
• RM-493 Treatment Trial in Proopiomelanocortin (POMC) Deficient PatientsStatus unknownNCT02507492Phase 2
• Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RM-493 Administered to Healthy, Obese, Non-diabetic VolunteersCompletedNCT02431442Phase 1
• Effects of RM-493 on Energy Expenditure in Obese IndividualsCompletedNCT01867437Phase 1

← Setmelanotide overview